Study Reveals Increased Hospitalization Risk for HFpEF Patients on Beta‑Blockers

The analysis of the TOPCAT trial data indicates that patients with heart failure with preserved ejection fraction who continue beta‑blocker therapy are significantly more likely to experience disease progression that requires hospital care. The risk jump of roughly 74 % suggests that slowing the heart’s rhythm may inadvertently raise intracardiac pressures in hearts that already struggle to relax. This pressure buildup can aggravate fluid retention, breathing difficulties, and swelling in the lower limbs—symptoms that drive emergency visits. While the study does not advise patients to stop medication abruptly, it emphasizes that clinicians must weigh the pros and cons for each individual, especially when the therapeutic goal is to manage hypertension, arrhythmias, or post‑myocardial‑infarction protection.